Obliviously biosimilars or biogenerics will replace due to low cost but safety of biopharmaceuticals or biosimilar is big concern as manufacturing process cannot be replicated 100 percent.

Dear Lavina

All depends on regulations and region. EMA or FDA approved biosimilars are save. Remember that even in original drug batch to batch differences could be quite high. So batch to batch of original drug is not identical but only similar.

Current expectations in FDA/EMA/ICH region are very detailed so registration proces in highly regulated markets and biosimilar development is very laborious proces.

Check newest data - link below:

  Best regards,

http://www.biopharma-reporter.com/Markets-Regulations/Remsima-and-Inflectra-not-inferior-to-Remicade-NOR-SWITCH-study-finds